Rajesh Kumar
Stock Analyst at HSBC
(2.52)
# 2,379
Out of 4,989 analysts
23
Total ratings
60%
Success rate
11.92%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Upgrades: Hold | $675 → $700 | $751.99 | -6.91% | 3 | Aug 27, 2025 | |
| NVO Novo Nordisk | Downgrades: Hold | n/a | $61.40 | - | 1 | Jul 31, 2025 | |
| IQV IQVIA Holdings | Downgrades: Hold | $260 → $160 | $187.22 | -14.54% | 1 | Apr 25, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $27.11 | +54.92% | 1 | Apr 25, 2025 | |
| ABBV AbbVie | Upgrades: Buy | $185 | $222.47 | -16.84% | 3 | Jun 5, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $479.58 | +39.71% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $193.29 | +44.86% | 2 | Apr 17, 2024 | |
| UNH UnitedHealth Group | Upgrades: Hold | $460 | $336.69 | +36.62% | 2 | Apr 4, 2024 | |
| TEVA Teva Pharmaceutical Industries | Initiates: Buy | $13 | $18.35 | -29.16% | 1 | Dec 18, 2023 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Hold | $55 → $53 | $45.02 | +17.73% | 2 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $25.24 | +284.31% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $96.22 | +28.87% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $24.03 | +108.07% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $81.51 | +50.90% | 1 | Jul 14, 2023 |
Eli Lilly and Company
Aug 27, 2025
Upgrades: Hold
Price Target: $675 → $700
Current: $751.99
Upside: -6.91%
Novo Nordisk
Jul 31, 2025
Downgrades: Hold
Price Target: n/a
Current: $61.40
Upside: -
IQVIA Holdings
Apr 25, 2025
Downgrades: Hold
Price Target: $260 → $160
Current: $187.22
Upside: -14.54%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $27.11
Upside: +54.92%
AbbVie
Jun 5, 2024
Upgrades: Buy
Price Target: $185
Current: $222.47
Upside: -16.84%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $479.58
Upside: +39.71%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $193.29
Upside: +44.86%
UnitedHealth Group
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $336.69
Upside: +36.62%
Teva Pharmaceutical Industries
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $18.35
Upside: -29.16%
Bristol-Myers Squibb Company
Oct 27, 2023
Upgrades: Hold
Price Target: $55 → $53
Current: $45.02
Upside: +17.73%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $25.24
Upside: +284.31%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $96.22
Upside: +28.87%
Jul 14, 2023
Initiates: Buy
Price Target: $50
Current: $24.03
Upside: +108.07%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $81.51
Upside: +50.90%